In this Industry Ignited episode, U.S. Biologic leader Chris Przybyszewski traces a career spanning neuroscience, public health, medical devices, high-tech, and infectious disease—and how it shaped his “translator” leadership style that aligns diverse experts around clear goals, shared definitions, and measurable success. He unpacks lessons from funding science across venture capital, government, and philanthropy—matching missions and ROI while never wasting stakeholders’ time. 

Chris spotlights U.S. Biologic’s breakthrough: orally delivered, thermostable vaccines deployed via backyard pellet stations to immunize reservoir species (like mice) against Lyme—an innovation that demanded new chemistry, manufacturing, distribution, and regulatory pathways, plus a deliberate IP “minefield” strategy. Drawing parallels to industrial supply chains, he frames the company as a delivery business optimizing the right antigen to the right species at the right moment, and argues for One Health collaboration across animal, human, environmental, regulatory, and commercial domains. 

Looking ahead, he sees AI enabling rapid pathogen detection, antigen selection, regulatory mapping, and development acceleration—while emphasizing that real-world manufacturing and last-mile distribution still decide impact. Anchored by his mantra “find a way or make one,” Chris advises leaders to choose boldly, accept early wrong turns, iterate with discipline, and persevere toward outcomes that protect public health and economies worldwide.